North Run Capital’s Elevance Health ELV Stock Holding History

North Run Capital’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-115,000	Closed	-$19M	–	14
2017 Q1	$19M	Sell	115,000 -160,000	-58%	-$25.5M	6.76%	7
2016 Q4	$39.5M	Sell	275,000 -60,000	-18%	-$8.03M	12.07%	2
2016 Q3	$42M	Buy	+335,000	New	+$43.3M	6.59%	3

Other funds holding ELV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

North Run Capital's ELV Position: Q2 2017 in Review

North Run Capital sold out of Elevance Health (ELV) in Q2 2017, closing a stake of 115,000 shares — an estimated $19M sold.

North Run Capital first reported a position in ELV in Q3 2016 and held it in 3 quarters. The position peaked at $42M in Q3 2016. 852 funds tracked by Wall St. Rank hold ELV as of Q2 2017.

North Run Capital reported no remaining Elevance Health position as of Q2 2017 after selling out during the quarter.
North Run Capital sold 115,000 Elevance Health shares in Q2 2017, an estimated $19M.
North Run Capital first reported a position in Elevance Health in Q3 2016 and held it in 3 quarters.
North Run Capital's Elevance Health position peaked at $42M in Q3 2016.
852 funds tracked by Wall St. Rank held Elevance Health as of Q2 2017.

Based on North Run Capital's 13F filing for Q2 2017, filed 11 Aug 2017.